Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on February 6, 2009. The report addresses a specific corporate governance event regarding the appointment of an interim officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Ms. Evdoxia E. Kopsidas as Interim Principal Accounting Officer by the Board of Directors on February 6, 2009. Ms. Kopsidas, 43, had previously served as the Company's Director of Finance since October 2006. Prior to joining Novavax, she held controller positions at BioVeris Corporation and BioReliance Corporation.
Guidance, Outlook, and Risks
The filing states there are no material plans, contracts, or other arrangements entered into or amended in connection with Ms. Kopsidas's appointment. No guidance, outlook, or specific risk factors were disclosed in this document.
Investor Verification Checklist
- Verify the effective date of the Interim Principal Accounting Officer appointment (February 6, 2009).
- Confirm the professional background of the new appointee, specifically her tenure as Director of Finance since 2006.
- Note the absence of any compensatory arrangements or contracts tied to this specific appointment.